

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4059009

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
A.T. DEVELOPMENT SWITZERLAND SÀRL	08/30/2016
RECEIVING PARTY DATA	
Name:	ADC THERAPEUTICS S.A.
Street Address:	ROUTE DE LA CORNICHE 3B
City:	1066 EPALINGES
State/Country:	SWITZERLAND
PROPERTY NUMBERS Total: 7	
Property Type	Number
Application Number:	14434810
Application Number:	14434812
Application Number:	14434816
Application Number:	14434818
Application Number:	14434821
Application Number:	14434823
Application Number:	14434826
CORRESPONDENCE DATA	
Fax Number:	(414)277-0656
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	414-271-6560
Email:	mkeipdocket@michaelbest.com
Correspondent Name:	MICHAEL BEST & FRIEDRICH LLP
Address Line 1:	100 E. WISCONSIN AVENUE, SUITE 3300
Address Line 4:	MILWAUKEE, WISCONSIN 53703
ATTORNEY DOCKET NUMBER:	065435-9249 THRU 9255 US
NAME OF SUBMITTER:	CHARLENE L. YAGER
SIGNATURE:	/charlene l. yager/
DATE SIGNED:	09/20/2016
Total Attachments: 11	

source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page1.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page2.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page3.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page4.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page5.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page6.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page7.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page8.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page9.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page10.tif
source=19672110_065435-9249-9255-US00_-_ASSIGNMENT_-_as_filed_-_VB_to_AT_--_AT_to_ADC#page11.tif

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352
Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

ASSIGNMENT OF INVENTION & RELATED INTELLECTUAL PROPERTY RIGHTS

PARTIES

- (1) **VAN BERKEL, PATRICIUS HENDRIKUS CORNELIS** c/o Queen Mary BioEnterprises Innovation Centre, 42 New Road, London E1 2AX, United Kingdom (the **Inventor**);
- (2) **A.T. DEVELOPMENT SWITZERLAND SÀRL** incorporated and registered in Switzerland with UID: CHE-114.136.712 whose principal place of business and office is located at Route de la Corniche 3B, 1066 Epalinges, Switzerland (the **Employer**); and
- (3) **ADC THERAPEUTICS S.A.** (previously ADC Therapeutics Sàrl) incorporated and registered in Switzerland with UID CHE-461.408.645 whose registered office is at Route de la Corniche 3B, 1066 Epalinges, Switzerland (the **Assignee**).

BACKGROUND

- (A) The Inventor is an inventor of the Invention for which the Patent Applications have been or will be filed. The contributions of the Inventor to the Invention were made in the course of the duties of each Inventor as an employee of the Employer, and either the circumstances were such that an invention might reasonably have been expected to result from the carrying out of those duties, or the nature of those duties was such that the Inventor had a special obligation to further the interests of the Employer's undertaking.
- (B) The Inventor and the Employer believe that, either by operation of law or by virtue of an agreement entered into by the Inventor and the Employer before the making of the Invention, the Employer was, at the time the Invention was made, entitled to the whole of the property in the contributions of the Inventor to the Invention.
- (C) The Employer and the Assignee are both parties to a Development Master Services Agreement dated 1 April 2013 (the **DMSA**) which governs the supply of the Employer's services to the Assignee. Under this DMSA, the Employer has assigned all its rights, title and interest in, to and arising from the Invention and the Patent Applications to the Assignee.
- (D) In case the Employer for any reason was not, at the time the Invention was made, entitled to the whole of the property in the contributions of the Inventor to the Invention, and in order to provide documentary evidence that the

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352
Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

Assignee is the owner of both the legal title and the beneficial interest in the Patent Applications and in any contributions of the Inventor to the Invention, including any further contributions that the Inventor may make to the development or improvement of the Invention, the Inventor and the Employer have agreed to execute this Assignment to assign to the Assignee all their rights, title and interest in, to and arising from the Invention and the Patent Applications on the terms set out in this Assignment.

AGREED TERMS

1. INTERPRETATION

- 1.1 The definitions and rules of interpretation in this clause apply in this Assignment.

Completion Applications means the completion patent applications, short particulars of which are set out in Part 2 of the Schedule.

Future Applications means any future applications linked by one or more priorities to the Completion Applications and all matter contained in such future applications.

Invention means the invention or inventions entitled PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES, PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES, PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES, and PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES.

Patent Applications means the Priority Applications, the Completion Applications and the Future Applications and any and all:

- (a) national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

Priority Applications means the priority patent applications, short particulars of which are set out in Part 1 of the Schedule.

- 1.2 A **person** includes a natural person, corporate or unincorporated body (whether or not having separate legal personality) and that person's legal and personal representatives, successors and permitted assigns.

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

2. ASSIGNMENT

In consideration of the sum of £1 (sufficiency and receipt of which the Inventor expressly acknowledges), each of the Inventor and the Employer hereby assign absolutely to the Assignee all their right, title and interest in Canada, the United States and all other countries of the world in, to and arising from the Invention and, with effect from immediately prior to the filing of each, the Patent Applications including (but not limited to):

- (a) in respect of the Invention and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any Patent Application:
 - (i) the right to claim priority from and to prosecute and obtain grant of patents; and
 - (ii) the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country, region or territory in the world, each and any of the Patent Applications and to extend to or register in, or in respect of, any country, region or territory in the world any patent or other intellectual property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any Patent Application; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal proceedings and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership of the Inventions and the Patent Applications, whether occurring before on or after the date of this Assignment.

3. FURTHER ASSURANCE

Each Inventor and the Employer shall, at the Assignee's cost, perform all further acts and things, and execute all further documents, required by law or which the Assignee requests to vest in the Assignee the full benefit of the right, title and interest assigned to the Assignee under this Assignment, including (but not limited to):

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

- (a) documents required to be signed by or on behalf of the Inventor or the Employer in the course of any and all Canadian or United States or any other applications which relate to the Invention or to any inventions that shall be disclosed in any of the Patent Applications;
- (b) registration of the Assignee as applicant for, or proprietor of, the Patent Applications; and
- (c) assisting the Assignee in obtaining, defending and enforcing any of the Patent Applications, and assisting with any other proceedings which may be brought by or against the Assignee by any third party or in the resolution of any question concerning the Invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

4. POWER OF ATTORNEY

The Inventor, the Employer and the Assignee grant the firm of Mewburn Ellis LLP the power to insert in Part 3 of the Schedule to this Assignment any further identification of any existing or future patent applications in Canada or the United States or any other countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of the United States Patent Office or the Canadian Patent Office or any other patent office for the recordal of this Assignment. It is agreed that Mewburn Ellis LLP has represented only the Assignee and will continue to represent only the Assignee with respect to this Assignment.

5. ISSUE OF PATENTS

The Inventor and the Employer request the US Commissioner of Patents and the relevant authorities in all countries, regions and territories of the world to issue any patents granted for the Inventions or pursuant to any of the Patent Applications in the name of the Assignee (either alone or jointly with any co-applicant) in accordance with this Assignment.

6. WAIVER

No failure or delay by a party to exercise any right or remedy provided under this Assignment or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

shall preclude or restrict the further exercise of that or any other right or
remedy.

7. COUNTERPARTS

This Assignment may be executed in any number of counterparts, each of
which when executed shall constitute an original of this Assignment, but all
the counterparts shall together constitute the same agreement.

8. GOVERNING LAW AND JURISDICTION

This Assignment shall be governed by and construed in accordance with the
law of England and Wales. The parties agree that the courts of England and
Wales shall have exclusive jurisdiction to settle any dispute or claim that
arises out of or in connection with this Assignment.

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

Schedule: The Patent Applications

Part 1: Priority Applications

Country	Application No.	Application Date	Title
US	61/712924	12 October 2012	PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
US	61/712928	12 October 2012	PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
US	61/784460	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784477	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784525	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784291	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784308	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784328	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784233	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784249	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784270	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784362	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784383	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784421	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/798037	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/798072	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/798106	14 March 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US	61/784162	14 March 2013	PYRROLOBENZODIAZEPINE-

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

			ANTIBODY CONJUGATES
US	61/784191	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US	61/784207	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US	61/794922	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US	61/794954	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US	61/794997	14 March 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES

Part 2: Completion Applications

Application No.	Application Date	Title
PCT/EP2013/071341	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
EP 13795435.0	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
US 14/434812	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
AU 2013328619	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
BR BR1120150081738	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
CA 2887894	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
IN 1069/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
MX MX/A/2015/004416	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
NZ 707486	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
ZA 2015/02437	11 October 2013	PYRROLOBENZODIAZEPINE - ANTI- PSMA ANTIBODY CONJUGATES
KR 10-2015-7012364	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- PSMA ANTIBODY CONJUGATES
PCT/EP2013/071342	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- PSMA ANTIBODY CONJUGATES
EP 13785372.7	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- PSMA ANTIBODY CONJUGATES

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

US 14/434818	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES
PCT/EP2013/071343	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
EP 13788691.7	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
US 14/434810	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
AU 2013328621	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
BR BR1120150081770	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
CA 2887896	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
IN 1072/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
MX MX/A/2015/004423	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
NZ 707546	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
ZA 2015/02267	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
KR 10-2015-7012365	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES
PCT/EP2013/071346	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
EP 13785831.2	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
US 14/434816	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
AU 2013328623	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
BR BR1120150081746	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
CA 2887895	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
IN 1090/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
MX MX/A/2015/004449	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
NZ 707534	11 October 2013	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

ZA 2015/02428	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
KR 10-2015-7012366	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
PCT/EP2013/071349	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
EP 13785373.5	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US 14/434823	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
AU 2013328625	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
BR BR1120150082327	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
CA 2887897	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
IN 1094/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
MX MX/A/2015/004421	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
NZ 707543	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
ZA 2015/02523	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
KR 10-2015-7012367	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
PCT/EP2013/071350	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
EP 13785374.3	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
US 14/434821	11 October 2013	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES
PCT/EP2013/071352	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES
EP 13786186.0	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES
US 14/434826	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES
AU 2013328628	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES
BR BR11201500823686	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI- CD22 ANTIBODY CONJUGATES

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

CA 2887899	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
IN 1115/MUMNP/2015	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
MX MX/A/2015/004420	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
NZ 707490	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
ZA 2015/02524	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
KR 10-2015-7012368	11 October 2013	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES

Part 3: Identification of some, but not necessarily all, patent applications falling within the scope of clause 2 of this Assignment

Country/region	Application No.	Application Date	Title	Signature for Mewburn Ellis LLP

Assignment of invention and PCT/EP2013/071341; PCT/EP2013/071342;
PCT/EP2013/071343; PCT/EP2013/0171346; PCT/EP2013/017349; PCT/EP2013/071350;
PCT/EP2013/071352

Mewburn Ref: RJW/LP6936280; RJW/LP6936298; RJW/LP6936306; RJW/LP6936314;
RJW/LP6936330; RJW/LP6936348; RJW/LP6936355 & Client Ref: Patent 1 WO; Patent 2
WO; Patent 3 WO; Patent 4 WO; Patent 6 WO; Patent 7 WO; Patent 9 WO

Executed by **PATRICIUS
HENDRIKUS CORNELIS VAN
BERKEL** in the presence of:


SIGNATURE OF INVENTOR


SIGNATURE OF WITNESS

NAME: *LISA SKELTON*


ADDRESS: *1142 NEW ROAD, LONDON, E1 2AX*

OCCUPATION: *HEAD OF PROJECT MANAGEMENT*

DATE: *31/8/2016*

Executed by **A.T. DEVELOPMENT
SWITZERLAND SARL** acting by
Michael FORER, a director, in
the presence of:


SIGNATURE OF DIRECTOR


SIGNATURE OF WITNESS

NAME: *Dulce Goncalves*


ADDRESS: *Chemin de Fenix 42, 1095 Lutry, Switzerland*

OCCUPATION: *General Counsel*

DATE: *30 August 2016*

Executed by **ADC
THERAPEUTICS S.A.** acting by
Michael Forer, a director, in
the presence of:


SIGNATURE OF DIRECTOR


SIGNATURE OF WITNESS

NAME: *Dulce Goncalves*

ADDRESS: *Chemin de Fenix 42, 1095 Lutry, Switzerland*

OCCUPATION: *General Counsel*

DATE: *30 August 2016*